A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics.
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2017
At a glance
- Drugs GSK 2245035 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 30 Nov 2011 New trial record